IRVINE, Calif.--(BUSINESS WIRE)--Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, has closed a $25 million Series A-1 ...

IRVINE, Calif., January 11, 2025--(BUSINESS WIRE)--Immunis, Inc., a clinical-stage biotech developing multi-active biologics for age and disease-related immune dysregulation, has closed a $25 million ...